|Day's range||0.6000 - 0.9000|
Danaher (DHR) closed the most recent trading day at $232.21, moving +0.76% from the previous trading session.
With its stock down 8.6% over the past three months, it is easy to disregard Danaher (NYSE:DHR). But if you pay close...
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Beckman Coulter, a clinical diagnostics leader, today unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyzer per footprint. The DxI 9000 Analyzer can run up to 215 tests per hour per square meter (tests/hr/m2).
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on July 28, 2023 to holders of record on June 30, 2023.
Key Insights The projected fair value for Danaher is US$258 based on 2 Stage Free Cash Flow to Equity With US$239 share...
(Bloomberg) -- Catalent Inc. shares traded at their lowest in three years following cuts to its annual financial outlook that hurt investor confidence in the contract drug manufacturer.Most Read from BloombergPowell’s Bet Against Recession Looks Good — Minus the Credit Crunch and a DC StandoffTexas Mass Shooting’s Bloody Images Add to Fervor in Gun DebateWhy Airfares, Hotels and Cars Are Getting So Expensive for AmericansGoldman Shells Out $215 Million to End Case on Underpaying WomenMitch McCon
Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 10, 2023 at 10:00 a.m. PT. The audio will be simultaneously webcast on www.danaher.com.
Insiders at Danaher Corporation ( NYSE:DHR ) sold US$4.5m worth of stock at an average price of US$270 a share over the...
Aldevron, a leading global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, will expand its mRNA production capabilities to include lipid nanoparticle (LNP) encapsulation and aseptic fill-finish capabilities enabling mRNA cGMP manufacturing services from Master Cell Bank through to Drug Product. This new capability will support the production of therapeutic-scale clinical and commercial-stage mRNA therapies for cancers and genetic diseases, and clini
Honeywell's (HON) Q1 results benefit from strong performance of the Aerospace segment due to higher commercial aviation aftermarket sales. The company's improved guidance for 2023 holds promise.
Stocks got off to a tough start on Tuesday, as market participants looked closely at the latest slate of earnings results. United Parcel Service (NYSE: UPS) is a stalwart of the shipping industry, and its numbers say a lot about whether the e-commerce side of the consumer retail economy is firing on all cylinders. Meanwhile, Danaher (NYSE: DHR) gave its reading on the healthcare sector.
Danaher's (DHR) Q1 earnings and revenues beat estimates. However, a decline in the sale of COVID-related products weigh on the top line.
While the top- and bottom-line numbers for Danaher (DHR) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Danaher (DHR) delivered earnings and revenue surprises of 4.42% and 1.97%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the first quarter 2023. Net earnings refer to net earnings attributable to common shareholders.
Walmart, Chevron, Danaher, Intel and Lowe's are included in this Analyst Blog.
Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Chevron Corporation (CVX) and Danaher Corporation (DHR).
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Danaher (NYSE:DHR) has had a rough three months with its share price down 5.9%. But if you pay close attention, you...
In the latest trading session, Danaher (DHR) closed at $254.76, marking a -0.54% move from the previous day.
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In the latest trading session, Danaher (DHR) closed at $255.75, marking a +1.62% move from the previous day.
Contract drug manufacturer Catalent (NYSE: CTLT) was surely tempted to reach for the aspirin bottle on Monday. Bloomberg reported that morning that the conglomerate Danaher (NYSE: DHR) has dropped its pursuit of Catalent. Citing "people familiar with the matter," the Bloomberg report said Danaher is no longer considering making a buyout offer despite its earlier expression of interest.